Learn More
BACKGROUND It is unknown whether either the angiotensin-II-receptor blocker irbesartan or the calcium-channel blocker amlodipine slows the progression of nephropathy in patients with type 2 diabetes independently of its capacity to lower the systemic blood pressure. METHODS We randomly assigned 1715 hypertensive patients with nephropathy due to type 2(More)
BACKGROUND The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them(More)
The aim of this study was to assess the efficacy and safety of sitagliptin (MK-0431) as monotherapy in patients with type 2 diabetes mellitus and inadequate glycaemic control (HbA1c ≥7% and ≤10%) on exercise and diet. A total of 521 patients aged 27–76 years with a mean baseline HbA1c of 8.1% were randomised in a 1:2:2 ratio to treatment with placebo,(More)
Supplementary Table 2. Inclusion criteria. 1 Informed consent obtained before any trial related activities. (Trial related activities were defined as any procedure that would not have been performed during standard management of the subject). 2 Male or female ≥18 years of age. 3 Type 2 diabetes mellitus (diagnosed clinically) for ≥6 months. 4 Current(More)
BACKGROUND Patients with diabetes have increased risk for adverse cardiovascular events. Angiotensin-converting enzyme inhibitors are protective in type 1 diabetes. However, no definitive studies have examined the use of angiotensin-receptor blockers in patients with type 2 diabetes and overt nephropathy. The primary outcomes of the Irbesartan Diabetic(More)
OBJECTIVE The aim of this trial was to evaluate the effects of alpha-lipoic acid (ALA) on positive sensory symptoms and neuropathic deficits in diabetic patients with distal symmetric polyneuropathy (DSP). RESEARCH DESIGN AND METHODS In this multicenter, randomized, double-blind, placebo-controlled trial, 181 diabetic patients in Russia and Israel(More)
OBJECTIVE Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) is a multinational, randomized, controlled trial designed to compare the effects of prandial versus fasting glycemic control on risk for cardiovascular outcomes in patients with type 2 diabetes after acute(More)
BACKGROUND Type 1 diabetes results from autoimmune destruction of insulin-producing pancreatic beta cells. The 60 kDa heat-shock protein (hsp60) is one of the known target self antigens. An immunomodulatory peptide from hsp60, p277, arrested beta-cell destruction and maintained insulin production in newly diabetic NOD mice. We did a randomised,(More)
OBJECTIVE The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add-on to metformin therapy in patients with moderately severe (hemoglobin A(1c) >or= 8.0% and <or= 11.0%) type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS This was a multinational, randomized, placebo-controlled, parallel-group, double-blind study(More)